Literature DB >> 16702050

Drug-induced psoriasis: an evidence-based overview and the introduction of psoriatic drug eruption probability score.

Emi Dika1, C Varotti, F Bardazzi, H I Maibach.   

Abstract

Psoriasis is a common skin disorder that needs a long-term management, not only because, of its prevalence but also because of the profound impact it can have on patients quality of life. Drugs may result in exacerbation of a preexisting psoriasis, in induction of psoriatic lesions on clinically uninvolved skin in patients with psoriasis, or in precipitation of the disease in persons without family history of psoriasis or in predisposed individuals. The knowledge of the drugs that may induce, trigger, or exacerbate the disease is of primary importance in clinical practice. By reviewing the literature, there are many reports on drug-induced psoriasis, but the data are not univocal. We propose, when possible, the use of a probability score from the authors to obtain a better classification and further understanding of drug-induced psoriasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702050     DOI: 10.1080/15569520500536568

Source DB:  PubMed          Journal:  Cutan Ocul Toxicol        ISSN: 1556-9527            Impact factor:   1.820


  8 in total

1.  A Case of Tumor Necrosis Factor-alpha Inhibitors-induced Pustular Psoriasis.

Authors:  Jae-Jeong Park; Seung-Chul Lee
Journal:  Ann Dermatol       Date:  2010-05-18       Impact factor: 1.444

Review 2.  The role of xenobiotics in triggering psoriasis.

Authors:  Jasna Grželj; Marija Sollner Dolenc
Journal:  Arch Toxicol       Date:  2020-08-24       Impact factor: 5.153

3.  Paradoxical Side Effect Related With Anti-Tumor Necrosis Factor Alpha Treatment.

Authors:  Ayhan Aşkın; Ece Güvendi; Aliye Tosun; Ümit Seçil Demirdal
Journal:  Med Arch       Date:  2017-04

4.  Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice by inhibiting the maturation and activation of dendritic cells.

Authors:  Yujiao Meng; Mingxing Wang; Xiangjiang Xie; Tingting Di; Jingxia Zhao; Yan Lin; Xiaolong Xu; Ningfei Li; Yating Zhai; Yan Wang; Ping Li
Journal:  Int J Mol Med       Date:  2017-03-21       Impact factor: 4.101

5.  Serum Metabolomic Profiling Reveals the Amelioration Effect of Methotrexate on Imiquimod-Induced Psoriasis in Mouse.

Authors:  Jiaxin Zong; Jieyi Cheng; Yuanfeng Fu; Jing Song; Weisong Pan; Li Yang; Ting Zhang; Mingmei Zhou
Journal:  Front Pharmacol       Date:  2020-11-19       Impact factor: 5.810

6.  Topical astilbin ameliorates imiquimod-induced psoriasis-like skin lesions in SKH-1 mice via suppression dendritic cell-Th17 inflammation axis.

Authors:  Qingqing Xu; Zhaoyang Liu; Zhiqiang Cao; Yongjian Shi; Ning Yang; Guangshang Cao; Chunmin Zhang; Rong Sun; Chunhong Zhang
Journal:  J Cell Mol Med       Date:  2022-01-12       Impact factor: 5.310

7.  Paradoxical Reaction to Golimumab: Tumor Necrosis Factor α Inhibitor Inducing Psoriasis Pustulosa.

Authors:  Marien Siqueira Soto Lopes; Beatriz Moritz Trope; Maria Paula Rua Rochedo Rodriguez; Rachel Lima Grynszpan; Tullia Cuzzi; Marcia Ramos-E-Silva
Journal:  Case Rep Dermatol       Date:  2013-11-07

Review 8.  Drug-induced psoriasis: clinical perspectives.

Authors:  Deepak Mw Balak; Enes Hajdarbegovic
Journal:  Psoriasis (Auckl)       Date:  2017-12-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.